Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INV-102 in Acute Infectious Keratoconjunctivitis
NCT05636228Phase 2Completed
- Sponsor
- Invirsa
- Start
- Jun 2023
- Primary completion
- Aug 2024
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in acute infectious keratoconjunctivitis comparing INV-102 0.7% Three Times per Day (TID) with Vehicle TID (2 arms). Primary endpoint: Change in Combined Clinical Score at Day 8. Started Jun 2023; status: completed.
02
Drugs
INV-102
03
Conditions
acute infectious keratoconjunctivitis
Beyond the preview
Go deeper on NCT05636228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05636228.